Adamis Pharmaceuticals Announces Private Placement

Adamis Pharmaceuticals Announces Private Placement 
SAN DIEGO, CA -- (Marketwired) -- 07/01/13 --  Adamis Pharmaceuticals
Corporation (OTCQB: ADMP) announced today that it has completed a
private placement financing transaction pursuant to which it issued
senior secured convertible promissory notes and warrants to purchase
up to 13,004,316 shares of common stock, to a small number of
institutional investors and received gross cash proceeds of
$5,300,000. The notes have an aggregate principal amount of
$6,502,158, which includes $613,271 from the exchange of a previously
outstanding convertible note. 
Net proceeds from this financing will be used to help fund the
continued operations of the company, advance some of the company's
product candidates, and enable any potential future acquisition of
products, assets or technologies to bolster the company's pipeline.  
"We believe this offering will be beneficial to our shareholders as
we strengthen our balance sheet and continue to move closer to
achieving the goals described in my May 3, 2013 letter to
shareholders," said Dr. Dennis J. Carlo, CEO and President of Adamis. 
Additional information about the transaction is contained in the
company's Form 8K filing with the Securities and Exchange Commission. 
About Adamis Pharmaceuticals Corporation 
Adamis Pharmaceuticals Corporation is a biopharmaceutical company
engaged in the development and commercialization of specialty
pharmaceutical and biotechnology products in the therapeutic areas of
respiratory disease, allergy, oncology and immunology. Adamis
currently has three products in its specialty pharmaceutical product
pipeline, including the Epinephrine Injection PFS syringe product for
use in the emergency treatment of anaphylaxis, APC-1000 for the
treatment of asthma and chronic obstructive pulmonary disease, and
APC-3000, an HFA inhaled nasal steroid product for the treatment of
allergic rhinitis. The Company's biotechnology efforts are focused on
the development of therapeutic vaccine product candidates and cancer
drugs for patients with unmet medical needs in the multi-billion
dollar global cancer markets. Its products under research and
development include TeloB-VAX, a novel cell-based therapeutic cancer
vaccine and three drugs: and APC-100, APC-200, and APC-300, for the
treatment of prostate cancer. 
Forward Looking Statements 
This press release contains forward-looking statements. These
statements relate to future events or our future results of
operations or future financial performance, including, but not
limited to the following statements: the company's beliefs concerning
the ability of its product candidates to compete successfully in the
market; the company's beliefs concerning the safety and effectiveness
of its product candidates; the results of any future clinical trials
that the company may conduct relating to its product candidates; the
ability to fund future product development; future revenues expected
from any of its product candidates, assuming that they are developed
and approved for marketing by the FDA and other regulatory
authorities; and the intellectual property protection that may be
afforded by any patents or patent applications relating to its
products and product candidates. Statements in this press release
concerning future events depend on several factors beyond the
company's control, including receipt of adequate funding to support
these activities, market conditions, and the regulatory approval
process. These statements are only predictions and involve known and
unknown risks, uncertainties and other factors, which may cause
Adamis' actual results to be materially different from these
forward-looking statements. Certain of these risks, uncertainties,
and other factors are described in greater detail in Adamis' filings
from time to time with the SEC, which Adamis strongly urges you to
read and consider, all of which are available free of charge on the
SEC's web site at http://www.sec.gov. Except to the extent required
by law, Adamis expressly disclaims any obligation to update any
forward-looking statements.  
Contact Adamis 
David J. Marguglio
SVP - Corporate Development
(858) 412-7950
dmarguglio@adamispharma.com 
 
 
Press spacebar to pause and continue. Press esc to stop.